Theodore S. Nowicki
YOU?
Author Swipe
View article: Supplemental Table 6 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Supplemental Table 6 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Incidence of hypophosphatemia and AKI following CAR-T cell infusion.
View article: Figure S1 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Figure S1 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Figure S1. Nadir serum electrolyte concentrations grouped by patient ICANS status.
View article: Figure S4 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Figure S4 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Figure S4. Association of hypophosphatemia incidence by ICANS grade.
View article: Figure S2 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Figure S2 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Figure S2. Trends in serum electrolyte concentrations following CAR T-cell infusion grouped by patient ICANS status.
View article: Figure S8 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Figure S8 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Figure S8. Baseline and change in kidney function following CAR T therapy grouped by patient ICANS status.
View article: Figure S5 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Figure S5 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Figure S5. Associations between pre-infusion tumor burden and ICANS and hypophosphatemia.
View article: Supplemental Table 2 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Supplemental Table 2 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Range and interquartile range of nadir serum electrolyte values in patients with and without ICANS.
View article: Supplemental Table 4 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Supplemental Table 4 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Stratification of CRS, ICANS, and hypophosphatemia incidence rates by pre-emptive treatment with tocilizumab.
View article: Supplemental Figure Legends from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Supplemental Figure Legends from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Supplemental Figure Legends
View article: Figure S6 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Figure S6 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Figure S6. Histogram plots of nadir phosphorus values stratified by ICANS status.
View article: Supplemental Table 3 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Supplemental Table 3 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Incidence of hypophosphatemia and ICANS in patients who developed CRS (n = 433).
View article: Figure S7 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Figure S7 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Figure S7. Coincidence of serum hypocalcemia with hypophosphatemia.
View article: Supplemental Table 1 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Supplemental Table 1 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Neurological adverse events included within each neurological adverse event category for CAR T-cell recipients.
View article: Figure S3 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Figure S3 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Figure S3. ICANS incidence and time to symptom onset.
View article: Supplemental Table 5 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Supplemental Table 5 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Correlation between ICANS, CRS, and various electrolyte derangements with categories of neurological adverse events reported in CAR T-cell recipients.
View article: Figure S2 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Figure S2 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Figure S2. Trends in serum electrolyte concentrations following CAR T-cell infusion grouped by patient ICANS status.
View article: Supplemental Table 4 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Supplemental Table 4 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Stratification of CRS, ICANS, and hypophosphatemia incidence rates by pre-emptive treatment with tocilizumab.
View article: Figure 2 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Figure 2 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
ICANS incidence and symptom duration in patients with various electrolyte derangements stratified by receipt of any repletion of the deficient electrolyte. ICANS incidence (top row, error bars represent 95% confidence interval (CI) in pati…
View article: Figure S7 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Figure S7 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Figure S7. Coincidence of serum hypocalcemia with hypophosphatemia.
View article: Figure S8 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Figure S8 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Figure S8. Baseline and change in kidney function following CAR T therapy grouped by patient ICANS status.
View article: Figure S6 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Figure S6 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Figure S6. Histogram plots of nadir phosphorus values stratified by ICANS status.
View article: Figure 1 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Figure 1 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Incidence of ICANS in patients stratified by the presence or absence of electrolyte derangements. Kaplan–Meier analyses comparing time to ICANS for patients stratified by the presence or absence of electrolyte derangements including (A) hy…
View article: Supplemental Table 6 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Supplemental Table 6 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Incidence of hypophosphatemia and AKI following CAR-T cell infusion.
View article: Data from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Data from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
A common complication of chimeric antigen receptor (CAR) T-cell therapy is immune effector cell–associated neurotoxicity syndrome (ICANS), which presents with encephalopathy, aphasia, inattention, somnolence, seizures, weakness, or cerebra…
View article: Supplemental Table 5 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Supplemental Table 5 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Correlation between ICANS, CRS, and various electrolyte derangements with categories of neurological adverse events reported in CAR T-cell recipients.
View article: Figure 3 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Figure 3 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Correlation between ICANS, CRS, and various electrolyte derangements with categories of neurological adverse events reported in CAR T-cell recipients. Data are represented as a bar graph showing Spearman rank correlation. Solid bars repres…
View article: Supplemental Table 1 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Supplemental Table 1 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Neurological adverse events included within each neurological adverse event category for CAR T-cell recipients.
View article: Table 1 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Table 1 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Demographics, outcomes, and selected laboratory values of patients treated with anti-CD19 CAR T-cell therapy stratified by ICANS status
View article: Figure S5 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Figure S5 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis Open
Figure S5. Associations between pre-infusion tumor burden and ICANS and hypophosphatemia.